ArticleCureus2026
Clinical and Metabolic Associations of Metabolic Dysfunction-Associated Steatotic Liver Disease in Young Adults: A Cross-Sectional Analysis.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized as the hepatic manifestation of systemic metabolic dysfunction and is closely associated with obesity, dyslipidaemia, insulin resistance, and metabolic syndrome. However, evidence regarding its burden and metabolic correlates among apparently healthy young adults remains limited. This study evaluated the prevalence of MASLD and its association with clinical, anthropometric, metabolic, and hepatic parameters in a young adult population.
methodsThis hospital-based cross-sectional study included 154 apparently healthy adults aged 20-40 years. Clinical evaluation, anthropometric measurements, biochemical investigations, abdominal ultrasonography, and transient elastography (FibroScan®) were performed. Hepatic steatosis was assessed using ultrasonography and controlled attenuation parameter (CAP), while liver fibrosis was evaluated using liver stiffness measurement (LSM) and the aspartate aminotransferase (AST)-to-platelet ratio index (APRI). Participants were categorized into MASLD and non-MASLD groups, and comparisons were performed using appropriate statistical tests.
resultsUltrasonographic evidence of MASLD was observed in 86 participants (55.8%). Compared with the non-MASLD group, participants with MASLD had significantly higher systolic and diastolic blood pressure, body weight, waist circumference, hip circumference, body mass index, waist-to-hip ratio, total cholesterol, low-density lipoprotein cholesterol, triglycerides, AST, alanine aminotransferase (ALT), APRI score, CAP, and LSM (all
conclusionMASLD was highly prevalent among apparently healthy young adults and was significantly associated with increased adiposity, adverse lipid profiles, elevated liver enzymes, and greater hepatic steatosis and fibrosis. These findings demonstrate significant associations between MASLD and adverse anthropometric, lipid, biochemical, and non-invasive hepatic parameters in this young adult cohort. Prospective multicentre studies are warranted to determine the temporal and clinical significance of these associations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.